These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 27121102)
1. miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression. Wang X; Zhu W; Zhao X; Wang P Int J Mol Med; 2016 Jun; 37(6):1636-42. PubMed ID: 27121102 [TBL] [Abstract][Full Text] [Related]
2. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. Sørensen BH; Dam CS; Stürup S; Lambert IH J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899 [TBL] [Abstract][Full Text] [Related]
3. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). Song L; Li Y; Li W; Wu S; Li Z J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379 [TBL] [Abstract][Full Text] [Related]
4. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734 [TBL] [Abstract][Full Text] [Related]
6. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692 [TBL] [Abstract][Full Text] [Related]
7. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185 [TBL] [Abstract][Full Text] [Related]
8. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079 [TBL] [Abstract][Full Text] [Related]
9. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620 [TBL] [Abstract][Full Text] [Related]
10. Role of copper transporters in resistance to platinating agents. Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997 [TBL] [Abstract][Full Text] [Related]
12. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416 [TBL] [Abstract][Full Text] [Related]
13. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550 [TBL] [Abstract][Full Text] [Related]
14. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Dmitriev OY Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266 [TBL] [Abstract][Full Text] [Related]
16. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Nakayama K; Miyazaki K; Kanzaki A; Fukumoto M; Takebayashi Y Oncol Rep; 2001; 8(6):1285-7. PubMed ID: 11605050 [TBL] [Abstract][Full Text] [Related]
17. Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines. Kassack MU; Stratenschulte C Int J Clin Pharmacol Ther; 2005 Dec; 43(12):597-8. PubMed ID: 16372532 [No Abstract] [Full Text] [Related]
18. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells. Doherty B; Lawlor D; Gillet JP; Gottesman M; O'Leary JJ; Stordal B Anticancer Res; 2014 Jan; 34(1):503-7. PubMed ID: 24403508 [TBL] [Abstract][Full Text] [Related]
19. ATP7B antisense oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line SKOV3ipl. Xu W; Cai B; Chen JL; Li LX; Zhang JR; Sun YY; Wan XP Int J Gynecol Cancer; 2008; 18(4):718-22. PubMed ID: 17944925 [TBL] [Abstract][Full Text] [Related]
20. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Miyashita H; Nitta Y; Mori S; Kanzaki A; Nakayama K; Terada K; Sugiyama T; Kawamura H; Sato A; Morikawa H; Motegi K; Takebayashi Y Oral Oncol; 2003 Feb; 39(2):157-62. PubMed ID: 12509969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]